Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $25.00 Price Target at JMP Securities

Key Points

• JMP Securities has raised its price target for Enanta Pharmaceuticals from $24.00 to $25.00, indicating a potential upside of 285.21% based on the stock's previous close.
• Recent reports have seen Enanta's rating upgraded from "sell" to "hold" by Wall Street Zen, reflecting a more positive outlook on the stock's performance.
• Enanta Pharmaceuticals is currently trading around $6.49 per share, with a 52-week low of $4.09 and a high of $13.43, amidst significant institutional investment in the company.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) had its price objective lifted by equities researchers at JMP Securities from $24.00 to $25.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a "market outperform" rating on the biotechnology company's stock. JMP Securities' price objective points to a potential upside of 285.21% from the stock's previous close.

ENTA has been the subject of several other reports. Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. HC Wainwright began coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a "buy" rating and a $20.00 price objective for the company.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $6.49 on Tuesday. The company's 50 day moving average price is $7.37 and its 200 day moving average price is $6.44. Enanta Pharmaceuticals has a fifty-two week low of $4.09 and a fifty-two week high of $13.43. The firm has a market capitalization of $138.76 million, a price-to-earnings ratio of -1.43 and a beta of 0.88.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.40. The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 149.57% and a negative return on equity of 79.83%. Equities analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at $5,968,000. Millennium Management LLC increased its position in shares of Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company's stock valued at $7,435,000 after buying an additional 449,945 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at $1,908,000. AQR Capital Management LLC increased its position in shares of Enanta Pharmaceuticals by 674.7% in the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company's stock valued at $1,971,000 after buying an additional 311,010 shares in the last quarter. Finally, Trexquant Investment LP increased its position in shares of Enanta Pharmaceuticals by 113.4% in the first quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company's stock valued at $1,601,000 after buying an additional 154,105 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.